78 articles about Polyphor
Polyphor AG and EnBiotix Inc. announced the closing of the merger of the two companies and the change of name of the combined company to Spexis AG.
Polyphor AG and EnBiotix Inc. announced that EnBiotix has completed a convertible debenture raise of USD 11 million to finance its future operations.
Polyphor and EnBiotix Announce Dosing of First Patient in a First-in-Human Clinical Trial of Inhaled Murepavadin
Polyphor AG and EnBiotix Inc. announced that the first subjects have been dosed in the first-in-human Phase I trial of a novel-class antibiotic murepavadin, delivered via the oral inhalation route.
Polyphor Shareholders Approve All Resolutions for the Planned Merger with EnBiotix at the Extraordinary General Meeting
Polyphor AG announced that its shareholders approved all proposals of the Board of Directors at the Extraordinary General Meeting on October 28, 2021, with a significant majority.
Polyphor Publishes Invitation to Extraordinary General Meeting and Announces Financial Results for the First Half 2021
Polyphor AG published the invitation to its Extraordinary General Meeting on October 28, 2021 and announced financial results for the first half of 2021.
Polyphor and EnBiotix Announce Signing of Merger Agreement and Sale of Inhaled Murepavadin to EnBiotix
Polyphor and EnBiotix Inc. announced that the companies have signed a merger agreement pursuant to which Polyphor acquires all of the outstanding capital stock of EnBiotix in exchange for shares of Polyphor common stock.
Polyphor said there has been no improvement in the results for FORTRESS, its Phase III global study for the possible treatment of patients with breast cancer.
Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide in Patients With Advanced HER2 Negative Breast Cancer
Polyphor AG announced that its global Phase III study, FORTRESS, evaluating balixafortide in combination with eribulin for the treatment of patients with HER2 negative, locally recurrent or metastatic breast cancer, did not meet its co-primary endpoint.
Polyphor Hosting Key Opinion Leader Roundtable on Covid-19: The Need for Novel Therapies for Severe Infections and the Potential Role of Balixafortide, a Selective CXCR4 Antagonist
Polyphor AG announced that it will host a key opinion leader roundtable on Covid-19, the need for novel therapies for severe infections and the potential role of balixafortide, a selective CXCR4 antagonist, on Thursday, June 10, 2021 at 8am Eastern Time/2pm Central European Time.
Polyphor's Balixafortide Demonstrates Consistent Dual Action Anti-Viral and Anti-Inflammatory Activity in COVID-19 Preclinical Trials
Conference call to discuss these results and the COVID-19 treatment landscape with 3 renowned scientific experts on June 10 at 8am ET/2pm CET
Polyphor AG a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance announced that the company will present at the UBS Global Healthcare Virtual Conference, taking place May 24 -26, 2021.
Phase III trial patient enrollment for balixafortide completed in Q4 2020 despite COVID-19. Results expected for ORR and PFS in Q2 and Q4 2021 respectively
Polyphor AG announced that it will publish its full-year financial results for 2020 on March 5 at 7:30am CET.
Polyphor to Take Part in Panel Discussion on Novel Oncology Targets at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
Polyphor AG announced that Gökhan Batur, Chief Executive Officer, will take part in a panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event on Thursday, January 7 from 8:00AM Eastern Standard Time.
Phase I safety, tolerability, and pharmacokinetic study in healthy volunteers expected to start in coming weeks following acceptance of a request for a Clinical Trial Authorization (CTA) granted by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
12/21/2020Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Polyphor Announces Third Positive Data Safety Monitoring Board (DSMB) Recommendation to Continue Phase III balixafortide FORTRESS Study Without Modifications
Polyphor AG announced that the clinical trial independent Data Safety Monitoring Board has completed the third, pre-specified interim analysis, of safety outcomes based on a data cut off of 401 randomized patients in the Phase III pivotal study with balixafortide in HER2 negative, locally recurrent or metastatic breast cancer patients.
Polyphor Receives an Additional USD 2.3 Million Award From CARB-X to Support Ongoing Development of a New Class of Antibiotics Targeting Multi-Drug Resistant Gram-Negative Pathogens
Polyphor AG announced the extension of its existing grant agreement with CARB-X, a global partnership led by Boston University dedicated to supporting the development of antibacterial products to diagnose, prevent and treat drug-resistant infections.
Polyphor receives award of up to USD $3.3 million from Cystic Fibrosis Foundation to support clinical development of inhaled antibiotic murepavadin
Award will help to fund planned Phase Ib/IIa study of inhaled murepavadin, a novel class antibiotic for the treatment of chronic Pseudomonas aeruginosa infections in cystic fibrosis